Search
Close this search box.
Search
Close this search box.

An industry leader in
biopharmaceutical contract manufacturing

About MabPlex

MabPlex provides global CDMO services in the development and manufacturing of biopharmaceuticals, including mAbs, recombinant proteins, ADCs and bispecifics. We offer our partners contract services from DNA to finished drug product. Our technical expertise allows us to provide effective high quality solutions for our partners biomanufacturing needs. At both our US R&D site and our manufacturing site in Yantai, China, MabPlex delivers our commitment to our partners through our quality manufacturing, meeting their expectations.

  • Comprehensive biologics development and manufacturing solutions for customers globally
  • Multiple Single Use 2000L Bioreactors for GMP Manufacturing
  • One of the few providers of large-scale ADC production worldwide
  • Services for pre-clinical studies through commercial production
  • Senior Management Team averaging over 20 years of industry experience globally

MISSION

MabPlex strives to be the world leader in providing CRO/CDO services enabling our clients to deliver top quality biopharmaceuticals to patients globally.

CUSTOMER FOCUSED

At MabPlex, we believe that our customers are the foundation of our business. We view you not just as customers, but rather as our partners. This is reflected in all parts of our company. Our quality by design approach puts our partners first by ensuring that the project is done correctly and with traceability. We deliver as promised on time at top quality. With this, we believe that the key to our success it to create long-term relationships.

Professional Integrity

From discussing your project to the final product we keep our partners in mind. All information is kept secure and confidential at every step. Our thoughts are, “how would we like to be dealt with if we were the customer?” We conduct ourselves with honesty in all of our dealings with partners, employees, and the community. Therefore, we deliver on time, quality, and best in value.

Service Excellence

Service excellence is reflected in how everyone at MabPlex thinks and acts. From your first interaction with us, you will see us promptly respond, provide consistent communication throughout your project, and a focus on providing a superior experience each and every time. Our quality culture is what drives our commitment to our partners and their biopharmaceuticals.

Our JOURNEY

June 2013
June 2013

MabPlex International, Ltd. was established.

March 2015
March 2015

Yantai headquarter moved to new location and production R&D center officially opened.

November 2015
November 2015

MabPlex USA, Inc. established.

December 2017
December 2017

Passed environmental management system and occupational health and safety management system certification.

January 2018
January 2018

Obtained Biotechnology Product "Pharmaceutical Production License".

May 2018
May 2018

Established San Diego R & D Center.

June 2018
June 2018

Established MabPlex Biomedical (Shanghai) Co., Ltd.

July 2018
July 2018

Passed the intellectual property management system certification.

September 2018
September 2018

GMP operation of MabPlex Phase II R &D and production center started.

September 2018
September 2018

Shandong province public service platform for antibody drug R&D and industrialization unveiled.

November 2018
November 2018

Completed first round of financing, with the financing amount of 390 million yuan.

April 2019
April 2019

MabPlex M2 GMP facility was put into commercial operation.

September 2019
September 2019

MabPlex was awarded “ADC CDMO Growth and Leadership Award" by Frost & Sullivan in USA.

November 2019
November 2019

MabPlex was selected as a national high-tech enterprise.

June 2020
June 2020

MabPlex completed the first B round of financing, with a financing amount of 510 million yuan.

July 2020
July 2020

MabPlex won the "Asia-Pacific Antibody and ADC Manufacturing Excellence Award".

January 2021
January 2021

MabPlex was selected as one of top enterprises in Shangdong Province.

July 2021
July 2021

MabPlex was selected as one of China's "Little Giant" enterprises.

August 2021
August 2021

MabPlex ranked as one of "Top 10 CROs" by Life Sciences Review 2021.

June 2022
June 2022

MabPlex was selected as one of "Top CMO in APAC 2022".

September 2022
September 2022

MabPlex International Biomedical Innovation Center and Operation Headquarters started construction.

April 2023
April 2023

MabPlex and SUMGEN reached a strategic cooperation for the commercial production of SG301 project.

July 2023
July 2023

MabPlex hosted "CDMO Efficiently Assist Drug Research and Development conference".

September 2023
September 2023

MabPlex was awarded as "Top CMO in China".

December 2023
December 2023

MabPlex was awarded as 2023 "Influential CDMO Company of the Year".

previous arrow
next arrow

LOCATIONS

MabPlex is headquartered in Yantai Economic and Development Area, a city in the northeast of the Shandong Province. It is bordered by both the Yellow Sea and the Bohai Sea. YEDA, Yantai Economic and Development Area, is one of the first 14 state-level development zones approved by the State Council of China in 1984. Yantai has attracted investments from more than 40 countries and regions, and more than 80 Fortune 500 Companies.

The biopharmaceutical industry in Yantai has prospered in the last two years. The number of biopharmaceutical corporations has reached 100, in which 13 companies have gone public in domestic and abroad market. In 2018, the total income of Yantai biopharmaceutical was 11 billion U.S dollars, with a year-on-year growth of 13.3%.

Yantai is also a tourist attraction.

SAN DIEGO